welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
Lower Limb Flexibility in Duchenne Muscular Dystrophy: Effects on Functional Performance
study id #: NCT03534349
condition: Duchenne Muscular Dystrophy, Performance, Flexibility
The investigator investigated the effect of lower limb flexibility on functional performance of children with Duchenne Muscular Dystrophy.
mechanism of action: No pharmaceutical intervention
last updated: November 21, 2018
start date: January 2017
estimated completion: June 2017
size / enrollment: 30
Thirty children whose functional levels were in 1 or 2 according to the Brooke Lower Extremity Functional Classification Scale were included in the study. Flexibilities of hamstrings, hip flexors, tensor fascia latae, and gastrocnemius muscles were evaluated in dominant lower limb. Popliteal angle test, hip flexor flexibility test, tensor fascia latae flexibility test and gastrocnemius flexibility test were used for flexibility asssessments. Functional performance was assessed with 6 Minute Walk Test (6 MWT) and Timed Performance Tests. The correlation between the flexibility of lower limb muscles' and performance tests were examined.
- 6 Minute Walk Test [ Time Frame: 6 Minute ]
The 6 Minute Walk Test (6MWT) is a standard test recently used to evaluate functional capacity in neuromuscular diseases, and found to be a safe and valid test that can be performed in Duchenne Muscular Dystrophy
- Timed Performance Test [ Time Frame: 3 minute ]
Timed performance tests such as 10 m walk, Gower's (from supine position to stand up), ascending/descending 4 steps were also performed. During these tests, the child's performance was recorded in seconds.
• Having a Duchenne Muscular Dystrophy diagnosis,
• Being in the ambulatory period and climbing four steps independently,
• To be able to cooperate the physiotherapist's directions,
• Not having any severe contracture in the lower limbs which may prevent assessments,
• Not having any injury or surgery involving the lower limbs during the last 6 months.
Children who did not provide these criteria and did not will to participate the study were excluded.
Oral Ifetroban in Subjects With Duchenne Muscular DystrophyDuchenne muscular dystrophy (DMD) is a d...
A Study to Evaluate the Safety and Tolerability of PF-06939926 Gene Therapy in Duchenne Muscular DystrophyThis is a first-in-human/first-in-patien...
PhaseOut DMD: a Phase 2, proof of concept, clinical study of utrophin modulation with ezutromidThis study investigates the hypothesis t...
Wave Life Sciences Receives US Orphan Drug and Rare Pediatric Disease Designations for WVE-210201Wave Life Sciences Ltd., a biotechnology...
CoQ10 and Prednisone in Non-Ambulatory DMDThis study will help determine if CoQ10 ...
Open Label Extension Study of HT-100 in Patients With DMDThis study is designed to provide 6-mont...
Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular DystrophyThe study is to demonstrate non-inferior...
PTC Therapeutics Celebrates the Fifth Anniversary of STRIVE Grant Awards by Announcing 2019 Award WinnersSOUTH PLAINFIELD, N.J., Sept. 6, 2019 ...
DMD clinical therapies II: P.133 The burden of participation in a clinical trial for boys with Duchenne muscular dys...Despite some medical breakthroughs in Du...
Solid Biosciences Reports Third Quarter 2018 Financial Results And Provides Business UpdateSolid Biosciences Inc. today reported fi...